Symposia 1 - The WHO System for Reporting Lung Cytopathology: The Rationale, Structure Categories and Application
Tracking # 20-1038294
$99999.00
There are no ratings for this course
Learn moreCourse overview
The WHO System for Reporting Lung Cytopathology has been developed and a book published by an expert editorial board of cytopathologists brought together by the WHO publisher IARC in a joint program with the International Academy of Cytology over the last eighteen months. The Reporting System is based on 5 well defined categories each of which has a risk of malignancy. The aim is to standardize the approach to reporting lung cytopathology including sputa, bronchial washes, bronchial brushes and fine needle aspiration biopsies. The Reporting System is centered on defined lesions and tumors that directly correlate with the WHO Classification of Tumors Thoracic 'blue book' and presents established key cytopathological diagnostic features for each lesion and a differential diagnosis based on the cytopathology and the use of ancillary testing to assist the diagnosis. The ultimate aim is to assist communication with clinicians and improve patient care. This symposium presents didactic lectures introducing the reporting system and providing information on the rationale, structure, reporting categories, and application of the system in routine reporting.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Clinical Laboratory Personnel
Clinical Laboratory Director
Clinical Laboratory Supervisor
Clinical Laboratory Technician
Clinical Laboratory Technologist
Public Health Director
Public Health Supervisor
Public Health Technologist
Disclosure statements
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.
The following individuals have reported financial relationships:
Michael Berry, SCT(ASCP)MBCM: Stockholder-Hologic
Lukas Bubendorf, MD, MIAC: Advisory Board - Astra Zeneca, Bayer, Eli Lilly, BMS, Takeda; Research Support - Sanofi, Systems Oncology, Thermo Fisher; Speaker's Fee - Thermo Fisher; Consultant – Systems Oncology, Janssen
Oscar Lin, MD, PhD: Consultant – Hologic and Jansen
Liron Pantanowitz, MD: Consultant – Hamamatsu, Advisory Board for Ibex
Martha B. Pitman, MD, FIAC: Consultant – Adenocyte, LLC
Donna K. Russell, MEd, CT(ASCP), HT(ASCP): Advisory Board – Hologic Scientific
Christopher J. VandenBussche, MD, PhD: Ad hoc advisory board panel and Consultant – Roche
Paul VanderLaan, MD, PhD: Consultant – Gala Therapeutics